Active Ingredient History
Lurtotecan is a semi-synthetic analog of camptothecin with antineoplastic activity. Liposomal lurtotecan was in clinical trials as a treatment for topotecan-resistant ovarian cancer, but was discontinued. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Carcinoma, Small Cell (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Lung Neoplasms (Phase 1)
Neoplasms (Phase 1)
Ovarian Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue